[go: up one dir, main page]

WO2024134964A1 - Dispositif de dosage de solution médicamenteuse - Google Patents

Dispositif de dosage de solution médicamenteuse Download PDF

Info

Publication number
WO2024134964A1
WO2024134964A1 PCT/JP2023/028704 JP2023028704W WO2024134964A1 WO 2024134964 A1 WO2024134964 A1 WO 2024134964A1 JP 2023028704 W JP2023028704 W JP 2023028704W WO 2024134964 A1 WO2024134964 A1 WO 2024134964A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug solution
connector
sealing member
administration device
liquid medicine
Prior art date
Application number
PCT/JP2023/028704
Other languages
English (en)
Japanese (ja)
Inventor
小川淳一
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Publication of WO2024134964A1 publication Critical patent/WO2024134964A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/04—Access sites having pierceable self-sealing members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/34—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub

Definitions

  • the present invention relates to a drug solution administration device that includes a drug solution container and a connector.
  • JP 2010-131064 A discloses a drug administration device that includes a housing and a syringe and plunger housed inside the housing. This drug administration device is provided with a hub luer lock that covers the drug solution discharge portion of the syringe. A cap is attached to the hub luer lock.
  • the drug solution outlet of the drug solution discharge section is blocked by a rubber packing.
  • a through hole is formed in the rubber packing.
  • the cap has a blocking plug portion.
  • the blocking plug portion is provided with an injection needle that is inserted into the patient's body.
  • the blocking plug portion is fitted into the through hole. This fitting positions the base end of the injection needle at the drug solution outlet.
  • the tip end of the injection needle is exposed from the blocking plug portion and is inserted into the patient's body.
  • the plunger moves inside the syringe toward the needle.
  • the liquid medicine inside the syringe is pushed by the moving plunger and administered to the patient through the needle.
  • an adapter in order to increase the pressure resistance of the drug discharge part of the syringe, can be provided around the outer periphery of the drug discharge part and a tube with a connector can be connected to the adapter by screwing.
  • the screws can gradually loosen while the drug administration device is being used. This requires the patient to periodically check how tightly the connector and adapter are fastened. Such periodic checking is cumbersome.
  • one idea is to provide a sealing member made of an elastic material at the drug solution discharge section and pierce the connecting needle into this sealing member.
  • a sealing member made of an elastic material at the drug solution discharge section and pierce the connecting needle into this sealing member.
  • the present invention aims to solve the above-mentioned problems.
  • a drug solution administration device includes a drug solution container, a closure body disposed at the tip of the drug solution container, and a connector attached to the closure body, the drug solution container having a drug solution storage section for storing the drug solution, a cylindrical drug solution discharge section disposed at the tip of the drug solution storage section, and a drug solution discharge hole formed in the drug solution discharge section for discharging the drug solution, the closure body having a sealing member made of an elastic body and liquid-tightly sealing the drug solution discharge hole, a fixing member for positioning and fixing the sealing member to the drug solution container, and an opening formed in the fixing member through which a portion of the sealing member is exposed, the sealing member being configured to be connected to the drug solution container via the closure body.
  • the connector is sandwiched between a fixing member and the drug solution discharge part, and has a connecting needle that passes through the opening of the fixing member and is pierced into the sealing member when the connector is attached to the occluder, a needle hub that holds the connecting needle, and a pressing part that presses the fixing member toward the drug solution discharge part when the connector is attached to the occluder, and the drug solution administration device has a first engagement part provided on the outside of the drug solution discharge part and a second engagement part provided on the connector, and the first engagement part and the second engagement part engage with each other when the connector is attached to the occluder.
  • the pressing portion that constitutes the connector presses the sealing member of the closure toward the drug solution discharge portion.
  • a first engagement portion provided on the outside of the drug solution discharge portion engages with a second engagement portion provided on the connector. Based on this engagement, the pressing portion maintains the state in which the sealing member is pressed toward the drug solution discharge portion. This improves the liquid-tightness between the drug solution discharge portion and the sealing member. Moreover, the liquid-tightness is maintained even when pressure is applied to the drug solution in the drug solution container to administer it to a patient.
  • the drug solution administration device includes a first extension portion that extends in a first direction from the base end to the tip of the drug solution discharge portion and includes the first engagement portion, and a second extension portion that extends in a second direction from the tip to the base end of the connector and includes the second engagement portion.
  • first extension portion allows the first engagement portion to be positioned at a desired position.
  • second extension portion allows the second engagement portion to be positioned at a desired position.
  • the drug solution administration device may have a guiding part and a guided part. In this configuration, while the connector is being attached to the obstruction body, the guiding part and the guided part come into contact with each other, and the guided part is guided by the guiding part.
  • the drug solution administration device includes a first extension portion that extends in a first direction from the base end to the tip of the drug solution discharge portion and includes the first engagement portion, and a second extension portion that extends in a second direction from the tip to the base end of the connector and includes the second engagement portion, and the first extension portion may include a guiding portion and the second extension portion may include a guided portion. Even in this configuration, when the connector is being attached to the closure, the guiding portion and the guided portion come into contact with each other and the guided portion is guided by the guiding portion.
  • the connecting needle can be moved toward the sealing member. Furthermore, in this configuration, since the first extending portion includes the guiding portion and the second extending portion includes the guided portion, the shapes of the drug solution container and the connector can be simplified.
  • the first extension portion or the second extension portion may be formed in a ring shape.
  • the first extension portion or the second extension portion is annular
  • the first engagement portion included in the first extension portion or the second engagement portion included in the second extension portion is provided in an annular shape. Therefore, it is possible to engage the first engagement portion and the second engagement portion over a wide range. As a result, the engagement between the first engagement portion and the second engagement portion is stable. This further improves the sealing ability of the occluding body against the drug solution discharge hole.
  • the connecting needle may pierce the sealing member while the guided portion is being guided by the guiding portion.
  • the connecting needle is pierced into the sealing member while preventing the connecting needle from shifting out of position relative to the sealing member. This makes it possible to prevent coring.
  • the first engagement portion may be provided on the drug solution container.
  • the drug solution administration device does not have a housing that contains the drug solution container, it is possible to connect the connector to the drug solution container.
  • the first engagement portion may be provided on the housing.
  • This configuration makes it possible to connect a connector to a housing in a drug solution administration device that has a drug solution container housed in the housing.
  • the connector may have a protrusion that is larger in diameter than the connecting needle and that protrudes from the needle hub toward the sealing member when the connector is attached to the closure. In this case, when the connector is attached to the closure, the protrusion is inserted into the opening of the fixing member and presses the part of the sealing member toward the drug solution discharge portion.
  • the pressing portion presses the closure toward the drug solution discharge portion
  • the protruding portion presses the sealing member toward the drug solution discharge portion. This makes it possible to achieve an even more liquid-tight seal between the drug solution discharge portion and the sealing member.
  • the pressing portion constituting the connector presses the sealing member of the closure toward the drug solution discharge portion of the drug solution container.
  • a first engagement portion provided on the outside of the drug solution discharge portion engages with a second engagement portion provided on the connector. Based on this engagement, the pressing portion maintains the state in which the sealing member is pressed toward the drug solution discharge portion. This improves the liquid-tightness between the drug solution discharge portion and the sealing member. This prevents the drug solution from leaking between the drug solution discharge portion and the sealing member.
  • the above engagement is maintained even when pressure is applied to the medicinal liquid in the medicinal liquid container in order to administer the medicinal liquid to a patient. Therefore, liquid tightness is maintained between the medicinal liquid discharge portion and the sealing member. In other words, even in this case, leakage of the medicinal liquid from between the medicinal liquid discharge portion and the sealing member is prevented.
  • FIG. 1 is a schematic cross-sectional view of a main part of a drug solution administration device according to an embodiment of the present invention.
  • FIG. 2 is a schematic side view of a main part of a liquid medicine container constituting the liquid medicine administration device.
  • FIG. 3 is a schematic cross-sectional view of the essential parts of the drug solution administration device when attachment of the connector to the obstructing body begins.
  • FIG. 4 is a schematic cross-sectional view of the essential parts of the drug solution administration device when the attachment of the connector to the obstructing body is completed.
  • FIG. 5 is a schematic cross-sectional view of a main part of a drug solution administration device according to a first modified example of the present invention.
  • FIG. 6 is a schematic cross-sectional view of a main portion of a liquid medicine container and a closing body provided in a liquid medicine administration device according to a second modified example of the present invention.
  • FIG. 1 is a schematic cross-sectional view of the main parts of a drug solution administration device 10 according to this embodiment.
  • the drug solution administration device 10 includes a drug solution container 100, a blocking body 200, and a connector 300.
  • the liquid medicine container 100 is, for example, a syringe.
  • the base end of the liquid medicine container 100 is an open end, and a gasket is disposed near the open end inside the liquid medicine container 100.
  • the gasket is provided at the tip of the plunger.
  • the plunger moves toward the tip of the liquid medicine container 100 based on the operation of the user or the actuator.
  • the gasket moves integrally with the plunger. Due to this movement, the liquid medicine M contained in the liquid medicine container 100 is pressed against the gasket and administered to the patient via the connecting needle 340. Since the above configuration is publicly known, illustrations of the gasket, plunger, actuator, etc. are omitted.
  • the drug solution container 100 has a drug solution storage section 102 and a drug solution discharge section 104.
  • the drug solution storage section 102 and the drug solution discharge section 104 are, for example, cylindrical in shape.
  • the inner and outer diameters of the drug solution discharge section 104 are smaller than the inner and outer diameters of the drug solution storage section 102.
  • a tapered section 106 is interposed between the drug solution storage section 102 and the drug solution discharge section 104.
  • the tapered section 106 tapers in diameter from the drug solution storage section 102 toward the drug solution discharge section 104.
  • the drug solution discharge section 104 extends so as to protrude from the center of the tip of the tapered section 106.
  • the hollow interior of the drug solution storage section 102 and the hollow interior of the tapered section 106 form the drug solution chamber 108.
  • the hollow interior of the drug solution discharge section 104 forms the drug solution discharge hole 112.
  • the drug solution discharge hole 112 is connected to the drug solution chamber 108.
  • the drug solution discharge hole 112 and the drug solution chamber 108 contain the drug solution M.
  • the diameter gradually decreases as it moves away from the drug solution storage section 102. This forms a diameter change section 110 at the tip of the drug solution discharge section 104.
  • An annular groove 114 is formed in a portion of the drug solution discharge section 104 closer to the base end than the diameter change section 110. The annular groove 114 is recessed diametrically inward of the drug solution discharge section 104.
  • the drug solution container 100 has a first extension portion 120.
  • the first extension portion 120 has an annular wall portion 121 protruding from the tip of the drug solution storage portion 102.
  • the first extension portion 120 extends along a first direction from the base end of the drug solution container 100 toward the tip.
  • the first extension portion 120 surrounds the drug solution discharge portion 104.
  • the length from the base end to the tip of the annular wall portion 121 is greater than the length from the base end to the tip of the drug solution discharge portion 104.
  • the outer diameter of the annular wall portion 121 is slightly smaller than the outer diameter of the drug solution storage portion 102.
  • the first extension portion 120 includes a guide portion 122.
  • the guide portion 122 includes a plurality of ribs 124 (see FIG. 2) and a first engagement portion 126.
  • the plurality of ribs 124 are provided at intervals in the circumferential direction of the annular wall portion 121.
  • Each of the plurality of ribs 124 extends from the base end of the annular wall portion 121 along the first direction.
  • the tip of the rib 124 is located at a predetermined position between the base end and the tip of the annular wall portion 121. In other words, the tip of the rib 124 does not reach the tip of the annular wall portion 121.
  • the guide portion 122 may be disposed at a position other than the first extension portion 120.
  • the first engaging portion 126 is provided at the tip of the annular wall portion 121.
  • the first engaging portion 126 is a portion that bulges outward in the diameter direction of the annular wall portion 121 in a generally trapezoidal shape. Due to this bulge, the first engaging portion 126 is shaped like an annular claw that protrudes outward in the diameter direction of the annular wall portion 121 that constitutes the first extending portion 120.
  • the first extending portion 120 includes the guide portion 122 and the first engaging portion 126.
  • the side wall of the first engaging portion 126 has a first cam surface 128.
  • the first cam surface 128 is an inclined surface that has a large diameter on the base end side and a small diameter on the tip end side.
  • the occluder 200 has a sealing member 210 and a fixing member 250.
  • the sealing member 210 has a cylindrical portion 212, a plug portion 214, and a convex portion 216.
  • the plug portion 214 protrudes from a base end surface 218 of the cylindrical portion 212 in a frustum shape, a truncated cone shape, or a cylindrical shape.
  • the convex portion 216 protrudes from a tip end surface 220 of the cylindrical portion 212 in a frustum shape, a truncated cone shape, or a cylindrical shape.
  • the center of the plug portion 214, the center of the cylindrical portion 212, and the center of the convex portion 216 overlap each other.
  • the maximum diameter of the plug portion 214 and the maximum diameter of the convex portion 216 are smaller than the diameter of the cylindrical portion 212.
  • the stopper portion 214 is inserted into the drug solution discharge hole 112. In this state, the base end surface 218 of the cylindrical portion 212 abuts against the tip surface 130 of the drug solution discharge portion 104. Based on the above, the outlet opening 132 of the drug solution discharge hole 112 is blocked by the stopper portion 214, and the drug solution discharge hole 112 is sealed by the sealing member 210.
  • the sealing member 210 is made of elastic materials such as medical rubber materials (e.g., butyl rubber, isoprene rubber, butadiene rubber, etc.) or various elastomer materials.
  • the fixing member 250 is a hollow body having an internal space.
  • the fixing member 250 has a base portion 252 which is a base end, an annular portion 254, and a holding portion 256 which is a tip end.
  • the annular portion 254 is a portion located between the base portion 252 and the holding portion 256.
  • the outer diameter of the annular portion 254 is smaller than the maximum outer diameter of the base portion 252 and the maximum outer diameter of the holding portion 256 (not shown).
  • the fixing member 250 is formed of a synthetic resin material such as polyethylene, polypropylene, polycarbonate, polystyrene, acrylic, etc.
  • the fixing member 250 is formed of a metal material such as stainless steel, titanium alloy, aluminum alloy, etc.
  • Two engagement claws 260 are provided on the inner wall of the base portion 252.
  • the two engagement claws 260 protrude diametrically inward of the base portion 252 at positions spaced apart from each other by approximately 180°.
  • Two openings 262 are formed in the annular portion 254. The two openings 262 are spaced apart from each other by approximately 180°.
  • the holding portion 256 holds the sealing member 210.
  • the holding portion 256 is disposed inside the annular wall portion 121.
  • the holding portion 256 is formed with an insertion recess 264 recessed from the base end to the tip end, and an opening 266.
  • the internal space of the base portion 252 and the annular portion 254 communicates with the opening 266 via the insertion recess 264.
  • the opening 266 is a circular opening.
  • the diameter of the opening 266 is approximately equal to the inner diameter of the drug solution discharge hole 112 (outlet opening 132).
  • the insertion recess 264 accommodates the cylindrical portion 212 of the sealing member 210.
  • the tip end surface 220 of the cylindrical portion 212 abuts against the ceiling surface 268 of the insertion recess 264. In this way, the sealing member 210 is sandwiched between the drug solution discharge portion 104 and the fixing member 250 in the axial direction of the drug solution discharge portion 104.
  • the protrusion 216 of the sealing member 210 is inserted into the opening 266. In other words, the protrusion 216, which is part of the sealing member 210, is exposed to the opening 266.
  • the drug solution discharge portion 104 is inserted into the internal space of the base portion 252 and the annular portion 254.
  • the fixing member 250 is attached to the drug solution discharge portion 104 so as to cover the drug solution discharge portion 104 from the outside.
  • two engagement claws 260 provided in the base portion 252 are inserted into the annular groove 114 of the drug solution discharge portion 104.
  • the diameter changing portion 110 of the drug solution discharge portion 104 is inserted into the two openings 262 of the annular portion 254.
  • the two engaging claws 260 engage with the annular groove 114, and the diameter changing portion 110 engages with the two openings 262. Furthermore, the inner wall of the base portion 252 is in close contact with the outer peripheral wall of the drug solution discharge portion 104.
  • the fixing member 250 is held in the drug solution discharge portion 104. By holding the fixing member 250 in this manner in the drug solution discharge portion 104, the sealing member 210 is positioned and fixed between the drug solution discharge portion 104 and the fixing member 250.
  • the connector 300 has a cylindrical portion 302, a needle hub 304, and a pressing portion 306.
  • a side wall 307 of the cylindrical portion 302 constitutes a second extending portion 308.
  • the second extending portion 308 extends in a second direction from the tip end of the connector 300 toward the base end.
  • the side wall 307 is provided with two tongue portions 312 that are elastically deformable in the radial direction of the side wall 307.
  • the two tongue portions 312 are spaced apart from each other by approximately 180°.
  • a U-shaped slit 310 is formed in the side wall 307 so as to surround the tongue portions 312.
  • the tongue portions 312 extend along the second direction.
  • a claw-shaped second engagement portion 314 is provided on the inner surface of the tongue portion 312 facing the hollow interior of the tube portion 302.
  • the side wall of the second engagement portion 314 has a second cam surface 316.
  • the second cam surface 316 is an inclined surface with a large inner diameter on the base end side and a small inner diameter on the tip end side.
  • the inner surface at the base end of the side wall 307 of the tube portion 302 is guided while abutting against the first engaging portion 126 or the multiple ribs 124 constituting the guiding portion 122 (see Figures 3 and 4).
  • the inner surface at the base end of the side wall 307 is the guided portion 320 that is guided by the guiding portion 122. Therefore, the second extending portion 308 includes the second engaging portion 314 and the guided portion 320.
  • the guided portion 320 may be located in a location separate from the second extending portion 308.
  • the needle hub 304 and the pressing portion 306 are cylindrical portions extending from the ceiling wall of the tube portion 302 in the second direction.
  • the needle hub 304 and the pressing portion 306 are positioned in a concentric relationship.
  • the length of the needle hub 304 in the second direction is smaller than the length of the pressing portion 306 in the second direction.
  • the length of the pressing portion 306 in the second direction is smaller than the length of the tube portion 302 in the second direction.
  • the pressing portion 306 presses the tip surface 270 of the holding portion 256 of the fixing member 250.
  • the pressing portion 306 is not limited to a cylindrical shape.
  • the pressing portion 306 may be configured, for example, to be composed of a plurality of pressing pieces spaced apart in the circumferential direction so as to surround the connecting needle 340.
  • a retaining hole 330 extending in the second direction and a drug solution flow path 332 connected to the retaining hole 330 are formed in the center of the needle hub 304.
  • the tip of the connecting needle 340 is inserted into the retaining hole 330. This causes the connecting needle 340 to be held in the needle hub 304.
  • the retaining hole 330 and the connecting needle 340 are located on the central axis C2 of the connector 300 or the tube portion 302, as shown in FIG. 1.
  • the connecting needle 340 has an inner cavity 342.
  • the inner cavity 342 opens on the side of the connecting needle 340 near the base end of the connecting needle 340. This opening is a drug solution inlet 344.
  • the inner cavity 342 opens at the tip of the connecting needle 340.
  • This opening is a drug solution outlet 346.
  • the drug solution outlet 346 is connected to the drug solution flow path 332.
  • the base end of the connecting needle 340 passes through the opening 266 of the fixing member 250, penetrates the sealing member 210, and is inserted into the drug solution discharge hole 112.
  • the drug solution inlet 344 is immersed in the drug solution M in the drug solution discharge hole 112.
  • the drug solution discharge hole 112 and the drug solution flow path 332 are connected via the inner cavity 342 of the connecting needle 340.
  • connection needle 340 is made of a metal material such as stainless steel, copper alloy, titanium alloy, aluminum alloy, etc.
  • the connector 300 has a cylindrical connection part 350 that extends in a first direction from the ceiling wall of the cylindrical part 302.
  • an injection needle (not shown) is connected to the cylindrical connection part 350.
  • an infusion tube (not shown) may be connected to the cylindrical connection part 350, and an injection needle may be attached to the tip of the infusion tube.
  • the drug solution administration device 10 has a closure 200 attached to the drug solution container 100 as shown in FIG. 1. Specifically, the drug solution discharge section 104 is covered with the closure 200. In contrast, the connector 300 is not attached to the closure 200. The drug solution container 100 with the closure 200 attached and the connector 300 are separately sterilized.
  • the user When using the drug solution administration device 10, the user connects an injection needle, a liquid delivery tube, or the like to the cylindrical connection portion 350 of the connector 300, and then attaches the connector 300 to the occlusion body 200.
  • a typical example of a user is a patient, but the user is not limited to patients.
  • the user positions the connector 300 against the tip of the liquid medicine container 100 as shown in FIG. 1.
  • the connector 300 is moved closer to the liquid medicine container 100.
  • This movement causes the diametric end of the first engagement portion 126 to abut against the inner surface of the base end of the side wall 307 of the tubular portion 302.
  • This abutment causes the central axis C2 of the tubular portion 302 and the central axis C1 of the liquid medicine discharge portion 104 to overlap with precision. In other words, so-called centering is performed.
  • This prevents the connection needle 340 from being displaced relative to the central axis C1 of the liquid medicine discharge portion 104.
  • the connection needle 340 has not yet pierced the sealing member 210.
  • the user further moves the connector 300 from the state shown in FIG. 3 toward the base end of the drug solution container 100. During this movement, the inner surface at the base end of the side peripheral wall 307 remains in contact with the first engagement portion 126. Therefore, when the connector 300 moves toward the base end of the drug solution container 100, the tube portion 302 is guided by the first engagement portion 126.
  • the connector 300 moves further toward the base end of the drug solution container 100, the inner surface of the base end of the side peripheral wall 307 leaves the first engagement portion 126 and comes into contact with the multiple ribs 124. In this state, the connector 300 moves toward the base end of the drug solution container 100. Therefore, the tube portion 302 is guided by the multiple ribs 124.
  • the guided portion 320 provided on the connector 300 is guided by the guide portion 122 provided outside the drug solution discharge portion 104 on the drug solution container 100.
  • the tip of the connecting needle 340 reaches the opening 266 of the fixing member 250.
  • the tip of the connecting needle 340 passes through the opening 266 and penetrates the protrusion 216 inserted into the opening 266 of the sealing member 210.
  • the tip of the connecting needle 340 penetrates the protrusion 216 of the sealing member 210 after the diametric end of the first engaging portion 126 abuts against the inner surface of the base end of the side peripheral wall 307 of the tubular portion 302.
  • the cutting edge of the connecting needle 340 penetrates the convex portion 216 of the sealing member 210. Therefore, the cutting edge of the connecting needle 340 penetrates a predetermined portion of the convex portion 216 from a direction approximately perpendicular to the diameter direction of the convex portion 216. This prevents coring from occurring due to the cutting edge of the connecting needle 340 being tilted with respect to the central axis C1 of the drug solution discharge portion 104.
  • the second cam surface 316 of the second engagement portion 314 slides against the first cam surface 128 of the first engagement portion 126.
  • the second cam surface 316 rides up on the first cam surface 128.
  • the tongue portion 312 is elastically deformed. Specifically, the tongue portion 312 bends from the connection portion between the tongue portion 312 and the side peripheral wall 307 as a starting point toward the outside in the diameter direction of the tube portion 302. Therefore, the second engagement portion 314 easily passes through the first engagement portion 126.
  • the second engagement portion 314 protruding toward the inside of the tube portion 302 does not hinder the attachment of the connector 300 to the closure body 200.
  • the pressing portion 306 provided on the connector 300 abuts against the tip surface 270 of the holding portion 256 of the fixing member 250.
  • the second engagement portion 314 passes through the first engagement portion 126, and then the tongue portion 312 returns due to its elasticity to the inner diameter direction of the tube portion 302. As a result, the first engagement portion 126 and the second engagement portion 314 engage with each other, as shown in FIG. 4.
  • connection needle 340 penetrates the sealing member 210 and reaches the inside of the drug solution discharge hole 112 as shown in FIG. 4. This allows the drug solution discharge hole 112 and the drug solution flow path 332 to communicate via the drug solution inlet 344, inner cavity 342, and drug solution outlet 346 of the connection needle 340. Furthermore, the pressing portion 306 presses the tip surface 270 of the holding portion 256 of the fixing member 250 toward the tip surface 130 of the drug solution discharge portion 104. In other words, the pressing portion 306 applies a pressing force to the fixing member 250 toward the drug solution discharge portion 104.
  • This pressing force causes the fixed member 250 to move slightly along the drug solution discharge portion 104 to the end position of the movement of the drug solution discharge portion 104 on the base end side.
  • the engagement claw 260 provided on the fixed member 250 moves along the annular groove 114, and the diameter change portion 110 of the drug solution discharge portion 104 moves relatively along the opening 262 formed in the fixed member 250.
  • the sealing member 210 is sandwiched between the tip surface 130 of the drug solution discharge portion 104 and the ceiling surface 268 of the insertion recess 264 in the fixed member 250. Therefore, after the fixed member 250 moves to the end position, a pressing force is applied from the pressing portion 306, and the base end surface 218 of the cylindrical portion 212 in the sealing member 210 is tightly attached to the tip surface 130 of the drug solution discharge portion 104 with a large pressure. Furthermore, a plug portion 214 is inserted into the outlet opening 132 of the drug solution discharge portion 104. For the above reasons, the outlet opening 132 of the drug solution discharge hole 112 is liquid-tightly sealed by the sealing member 210. Therefore, it is possible to prevent the drug solution M from leaking between the outlet opening 132 and the sealing member 210.
  • the injection needle is inserted into the patient.
  • the plunger is operated by the user or the actuator.
  • the plunger and the gasket move together in the liquid medicine chamber 108 toward the tip of the liquid medicine container 100.
  • the liquid medicine M is then administered to the patient from the injection needle via the inner cavity 342, the liquid medicine outlet 346, and the liquid medicine flow path 332.
  • the liquid medicine M in the liquid medicine chamber 108 is also pushed by the gasket, and the liquid medicine M is replenished to the liquid medicine discharge hole 112.
  • the first engagement portion 126 and the second engagement portion 314 are maintained in engagement. This maintains the state in which the sealing member 210 is pressed against the medicinal liquid discharge portion 104. Therefore, even while the medicinal liquid M in the medicinal liquid chamber 108 is being pressed by the gasket, leakage of the medicinal liquid M from between the outlet opening 132 and the sealing member 210 is prevented.
  • a medicinal liquid administration device 20 according to a first modified example will be described with reference to FIG. 5. Note that, in the medicinal liquid administration device 20, components that are the same as those in the medicinal liquid administration device 10 are given the same reference numerals, and detailed descriptions thereof will be omitted.
  • the drug solution administration device 20 includes a connector 360.
  • the connector 360 has a protrusion 362 protruding from the needle hub 304.
  • the retaining hole 330 extends from the needle hub 304 to the protrusion 362.
  • the outer diameter of the protrusion 362 is smaller than the diameter of the opening 266. Therefore, the protrusion 362 can be inserted into the opening 266.
  • the protrusion 362 when the connector 360 is attached to the obstruction body 200, the protrusion 362 is inserted into the opening 266 and presses the convex portion 216. That is, in this case, in addition to the pressing portion 306 pressing the fixing member 250 toward the drug solution discharge portion 104, the protrusion 362 presses the sealing member 210 toward the drug solution discharge portion 104. This further improves the liquid-tightness between the tip surface 130 of the drug solution discharge portion 104 and the base end surface 218 of the sealing member 210.
  • a medicinal liquid administration device 30 according to a second modified example will be described with reference to FIG. 6. Note that, in the medicinal liquid administration device 30, components that are the same as those in the medicinal liquid administration devices 10 and 20 are given the same names, and detailed descriptions may be omitted.
  • the drug solution administration instrument 30 constitutes, for example, a drug solution administration device.
  • the drug solution administration instrument 30 includes a drug solution container 150 and a housing 158.
  • the drug solution container 150 is accommodated inside the housing 158.
  • an annular wall portion 161 is provided on the housing 158.
  • the annular wall portion 161 constitutes a first extension portion 160.
  • the annular wall portion 161 is provided with a plurality of ribs 164 and a first engagement portion 166.
  • the first engagement portion 166 and the plurality of ribs 164 constitute a first guide portion 162.
  • the first extension portion 160 includes the first guide portion 162.
  • the first engagement portion 166 has, for example, the same shape as the first engagement portion 126, and has a first cam surface 168.
  • Each of the ribs 164 has, for example, the same shape as each of the ribs 124.
  • the drug solution administration device 30 further includes, for example, a connector 300.
  • the connector 300 may be replaced with a connector 360 shown in FIG. 5.
  • the guided portion 320 of the connector 300 is guided by the first guiding portion 162 provided on the housing 158. Then, the second engaging portion 314 of the connector 300 engages with the first engaging portion 166 provided on the housing 158. This allows the drug solution administration device 30 to achieve the same effect as the drug solution administration device 10 or the drug solution administration device 20.
  • the annular wall portions 121, 161 are covered with the connectors 300, 360. That is, the connectors 300, 360 are located outside the annular wall portions 121, 161. Conversely, the annular wall portions 121, 161 may cover the connectors 300, 360. In this case, the connectors 300, 360 are located inside the annular wall portions 121, 161.
  • the present invention is not limited to the above disclosure, and various configurations may be adopted without departing from the gist of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un dispositif de dosage de solution médicamenteuse (10) qui comprend un récipient de solution médicamenteuse (100), un corps de fermeture (200) et un connecteur (300). Le corps de fermeture comporte un élément d'étanchéité (210) et un élément de fixation (250). Une ouverture (266) est formée dans l'élément de fixation. Le connecteur comporte une aiguille de connexion (340). Lorsque le connecteur est monté sur le corps de fermeture, l'aiguille de connexion est insérée dans l'élément d'étanchéité à travers l'ouverture. Le dispositif de dosage de solution médicamenteuse comprend également : une première partie de mise en prise (126) qui est disposée à l'extérieur d'une partie de décharge de solution médicamenteuse (104) ; et une seconde partie de mise en prise (314) qui est disposée sur le connecteur. La première partie de mise en prise et la seconde partie de mise en prise viennent en prise l'une avec l'autre lorsque le connecteur est monté sur le corps de fermeture.
PCT/JP2023/028704 2022-12-22 2023-08-07 Dispositif de dosage de solution médicamenteuse WO2024134964A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-205470 2022-12-22
JP2022205470 2022-12-22

Publications (1)

Publication Number Publication Date
WO2024134964A1 true WO2024134964A1 (fr) 2024-06-27

Family

ID=91588033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/028704 WO2024134964A1 (fr) 2022-12-22 2023-08-07 Dispositif de dosage de solution médicamenteuse

Country Status (1)

Country Link
WO (1) WO2024134964A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4947507Y1 (fr) * 1969-03-19 1974-12-26
JPS52112194U (fr) * 1976-02-20 1977-08-25
WO2018168989A1 (fr) * 2017-03-16 2018-09-20 テルモ株式会社 Dispositif d'administration de médicament liquide
WO2020195363A1 (fr) * 2019-03-26 2020-10-01 テルモ株式会社 Structure de raccordement et outil d'administration de médicaments liquides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4947507Y1 (fr) * 1969-03-19 1974-12-26
JPS52112194U (fr) * 1976-02-20 1977-08-25
WO2018168989A1 (fr) * 2017-03-16 2018-09-20 テルモ株式会社 Dispositif d'administration de médicament liquide
WO2020195363A1 (fr) * 2019-03-26 2020-10-01 テルモ株式会社 Structure de raccordement et outil d'administration de médicaments liquides

Similar Documents

Publication Publication Date Title
JP6873173B2 (ja) 薬物送達デバイス用のアダプタおよび前記アダプタをそこに装着するための方法
JP6335907B2 (ja) 薬剤送出装置用のアダプターおよびこのアダプターを薬剤送出装置に装着するための方法
KR100726297B1 (ko) 사용이 용이한 연결 장치
US8460250B2 (en) Medical container
CN107980006B (zh) 药物包装
EP2982408B1 (fr) Raccord
RU2552239C1 (ru) Герметизирующее устройство для контейнера
JP6046721B2 (ja) 液体投与具
WO2016181826A1 (fr) Doseur de médicament et seringue pré-remplie
EP2898912B1 (fr) Instrument d'administration de médicament
JP7413355B2 (ja) 接続構造及び薬液投与器具
US11311680B2 (en) Female syringe and syringe kit
WO2024134964A1 (fr) Dispositif de dosage de solution médicamenteuse
JP2024045522A (ja) 雄コネクタ
JP7573162B2 (ja) 医療用コネクタ
JP2010131064A (ja) 容器兼用注射器
KR100810158B1 (ko) 약품 분배 장치에 사용하기 위한 카트리지
JP7352818B2 (ja) バイアルアダプタ
JP6318691B2 (ja) 医療用栓体
JP6633956B2 (ja) 液体注入器具
EP4112102A1 (fr) Adaptateur de verrouillage, ensemble seringue et seringue pré-remplie
CN213490571U (zh) 用于小瓶的适配器
JP4476460B2 (ja) キャップ
WO2013145998A1 (fr) Ensemble d'administration de liquide
WO2025037461A1 (fr) Seringue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23906347

Country of ref document: EP

Kind code of ref document: A1